Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Gaia Shamis of Lifespy Advisors. Please go ahead. Thank you, Latonya, and good afternoon, everyone. Thank you for joining today to discuss Kintra Bio's second quarter 2026 financial and business results. I'm Gaia Shamis from Lifespy Advisors. Joining me on today's call are Thane Wettig, Chief Executive Officer, David DeLucia, Chief Financial Officer, and Carol Gadom, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about Kintra's bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, The Initiation, Enrollment, Design, Conduct and Results of Clinical Trials, Regulatory Strategies and Potential Regulatory Results, Research and Development Activities, Commercial Results and Results of Operations, Risks Related to Our Business, and Certain Other Business Matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kintra Bio's filing with the SEC, including our most recent Form 10-K and Form 10-Q. Kintra Bio does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting the company's financial results and business updates and a webcast of today's conference call can be found on the investor section of Kintra...